Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
110.47
+1.20 (1.10%)
Sep 14, 2026, 4:00 PM EDT - Market closed
Inhibrx Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | 1.3 | 0.2 | 1.8 | 1.32 | 7.23 | |
Revenue Growth | - | 550.00% | -88.89% | 36.88% | -81.81% | -43.89% |
Cost of Revenue | 103 | 113.03 | 177.84 | 191.64 | 101.6 | 71.44 |
Gross Profit | -103 | -111.73 | -177.64 | -189.84 | -100.29 | -64.21 |
Selling, General & Admin | 24.81 | 23.3 | 44.64 | 29.35 | 15.04 | 12.36 |
Operating Expenses | 24.81 | 23.3 | 44.64 | 29.35 | 15.04 | 12.36 |
Operating Income | -127.81 | -135.03 | -222.29 | -219.19 | -115.32 | -76.56 |
Interest Expense | -15.57 | -12.2 | -13.49 | -31.84 | - | - |
Interest & Investment Income | 5.37 | 7.55 | 10.94 | 11.92 | - | - |
Earnings From Equity Investments | - | - | - | -1.63 | - | - |
Other Non Operating Income (Expenses) | -0.17 | -0.38 | 0.08 | -0.58 | 0 | -5.2 |
EBT Excluding Unusual Items | -138.18 | -140.05 | -224.76 | -241.32 | -115.32 | -81.77 |
Merger & Restructuring Charges | - | - | -109.16 | -0.04 | - | - |
Other Unusual Items | - | - | 2,021 | - | - | - |
Pretax Income | -138.18 | -140.05 | 1,688 | -241.36 | -115.32 | -81.77 |
Income Tax Expense | 0 | 0 | 0 | 0 | 0 | 0 |
Net Income | -138.18 | -140.06 | 1,688 | -241.36 | -115.33 | -81.77 |
Net Income to Common | -138.18 | -140.06 | 1,688 | -241.36 | -115.33 | -81.77 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 16 | 15 | 15 | 12 | 40 | 38 |
Shares Outstanding (Diluted) | 16 | 15 | 15 | 12 | 40 | 38 |
Shares Change | 0.61% | 3.36% | 27.17% | -70.62% | 5.52% | 50.47% |
EPS (Basic) | -8.88 | -9.04 | 114.01 | -20.48 | -2.88 | -2.15 |
EPS (Diluted) | -8.88 | -9.04 | 112.62 | -20.48 | -2.88 | -2.15 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -131.9 | -129.83 | -197.01 | -197.9 | -91.5 | - |
Free Cash Flow Per Share | -8.47 | -8.38 | -13.15 | -16.80 | -2.28 | - |
Operating Margin | - | -10386.54% | -111143.50% | -12176.94% | -8769.81% | -1058.83% |
Profit Margin | - | -10773.46% | 843786.00% | -13408.94% | -8769.96% | -1130.80% |
Free Cash Flow Margin | - | -9986.54% | -98503.00% | -10994.56% | -6957.95% | - |
EBITDA | -125.6 | -132.54 | -220 | -217.99 | -114.1 | - |
D&A For EBITDA | 2.21 | 2.48 | 2.29 | 1.19 | 1.23 | - |
EBIT | -127.81 | -135.03 | -222.29 | -219.19 | -115.32 | -76.56 |
Revenue as Reported | - | 1.3 | 0.2 | 1.8 | 1.32 | 7.23 |